Skip to main content

Clinical Trials Using Daratumumab and Hyaluronidase-fihj

Review the clinical trials studying daratumumab and hyaluronidase-fihj on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

Testing the Use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Status: Active
Location: 597 locations
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Status: Active
Location: 524 locations
Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Status: Active
Location: 694 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 120 locations
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Status: Active
Location: 101 locations
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Kidney Failure
Status: Active
Location: 70 locations
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) with the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Status: Active
Location: 27 locations
Iberdomide-Combinations for the Treatment of Positive Minimal Residual Disease (>10-5) after Autologous Hematopoietic Cell Transplantation as Upfront Therapy in Patients with Multiple Myeloma, The COMMANDER Trial
Status: Active
Location: 5 locations
Iberdomide and Daratumumab for Reducing Residual Disease in Patients who Have Undergone Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma, IBEX Trial
Status: Active
Location: 4 locations
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Subcutaneous Daratumumab in the Upper Thigh versus the Abdomen in Patients with Multiple Myeloma of AL Amyloidosis
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
SX-682 in Combination with Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Daratumumab and Hyaluronidase-fihj before Standard Desensitization to Lower Donor-Specific Antibodies in Patients Undergoing Donor Bone Marrow or Peripheral Blood Stem Cell Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Daratumumab, Ixazomib, and Dexamethasone in Treating Patients with Relapsed or Refectory Amyloid Light Chain Amyloidosis
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Daratumumab and Hyaluronidase-fihj for the Treatment of Polyneuropathy Associated with MGUS
Status: Active
Location: 2 locations